AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8904935 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately brief advice from general practitioners
Number of subjects: 4500
Study 8904935 — intervention group
Group type: COMPARATOR
Intervention: Minimal advice from doctors
Number of subjects: 4500
Study 8904935 — intervention group
Group type: EXPERIMENTAL
Intervention: More involved intervention from doctors
Number of subjects: 4500
Study 8904935 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcement contact following a 2-hour training workshop
Number of subjects: 4500
Study 2052629 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric contractions with maximal effort
Number of subjects: 0
Study 2052629 — intervention group
Group type: COMPARATOR
Intervention: Concentric contractions with maximal effort
Number of subjects: 0
Study 2052629 — intervention group
Group type: COMPARATOR
Intervention: Eccentric contractions at equal power levels
Number of subjects: 0
Study 2052629 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric contractions at equal power levels
Number of subjects: 0
Study 7058424 — intervention group
Group type: EXPERIMENTAL
Intervention: Accurette endometrial sampler
Number of subjects: 42
Study 31636242 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex
Number of subjects: 102
Study 31636242 — intervention group
Group type: COMPARATOR
Intervention: Pyridostigmine-glycopyrrolate
Number of subjects: 102
Study 30946887 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI) 2 mg every 4 weeks (2q4)
Number of subjects: 466
Study 30946887 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI) 2 mg every 8 weeks after 5 monthly doses (2q8)
Number of subjects: 466
Study 30946887 — intervention group
Group type: COMPARATOR
Intervention: Laser treatment (control)
Number of subjects: 466
Study 28029326 — intervention group
Group type: EXPERIMENTAL
Intervention: O-DHAP (Ofatumumab 1,000 mg)
Number of subjects: 447
Study 28029326 — intervention group
Group type: COMPARATOR
Intervention: R-DHAP (Rituximab 375 mg/m2)
Number of subjects: 447
Study 26392096 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy (25 Gy in five daily fractions over 1 week)
Number of subjects: 98
Study 26392096 — intervention group
Group type: COMPARATOR
Intervention: Commonly used radiotherapy (40 Gy in 15 daily fractions over 3 weeks)
Number of subjects: 98
Study 23816898 — intervention group
Group type: EXPERIMENTAL
Intervention: Moving with device (MD)
Number of subjects: 22
Study 23816898 — intervention group
Group type: COMPARATOR
Intervention: Moving without device (MND)
Number of subjects: 22
Study 23816898 — intervention group
Group type: COMPARATOR
Intervention: Non‐moving (NM)
Number of subjects: 22
Study 21765361 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard amino acid intake (1.5 g · kg(‐1) · day(‐1))
Number of subjects: 9
Study 21765361 — intervention group
Group type: EXPERIMENTAL
Intervention: High amino acid intake (3.0 g · kg(‐1) · day(‐1))
Number of subjects: 9
Study 21765361 — intervention group
Group type: COMPARATOR
Intervention: Insulin infusion
Number of subjects: 9
Study 19357135 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg/day low molecular weight heparin (LMWH)
Number of subjects: 150
Study 19357135 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 150
Study 16967770 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg extension exercise at 30%, 60%, and 90% of 1-RM
Number of subjects: 20
Study 16268981 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm water immersion (33-34 degrees C)
Number of subjects: 12
Study 16268981 — intervention group
Group type: COMPARATOR
Intervention: Land conditions
Number of subjects: 12
Study 10322586 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric isokinetic knee strength and power assessment using Cybex 6000 System
Number of subjects: 96
Study 8565163 — intervention group
Group type: EXPERIMENTAL
Intervention: Attenuation-corrected (AC) 99mTc-sestamibi SPECT
Number of subjects: 119
Study 8565163 — intervention group
Group type: COMPARATOR
Intervention: Uncorrected (NC) 99mTc-sestamibi SPECT
Number of subjects: 119
Study 1928019 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse Prevention Therapy (RPT)
Number of subjects: 42
Study 1928019 — intervention group
Group type: COMPARATOR
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 42
Study 1928019 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse Prevention Therapy (RPT) among severe users
Number of subjects: 42
Study 1928019 — intervention group
Group type: COMPARATOR
Intervention: Interpersonal Psychotherapy (IPT) among severe users
Number of subjects: 42
Study 7095565 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (two tablets four times a day for 24 hours)
Number of subjects: 10
Study 7095565 — intervention group
Group type: EXPERIMENTAL
Intervention: Bufferin (two tablets four times a day for 24 hours)
Number of subjects: 10
Study 7095565 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (two tablets four times a day for 24 hours)
Number of subjects: 10
Study 7095565 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two tablets four times a day for 24 hours)
Number of subjects: 10
Study 31655876 — intervention group
Group type: EXPERIMENTAL
Intervention: QuikClot Radial hemostatic pad (QC)
Number of subjects: 200
Study 31655876 — intervention group
Group type: COMPARATOR
Intervention: Standard mechanical compression (SC)
Number of subjects: 200
Study 31655876 — intervention group
Group type: EXPERIMENTAL
Intervention: QuikClot Radial hemostatic pad (QC) in TRA subgroup
Number of subjects: 200
Study 31655876 — intervention group
Group type: COMPARATOR
Intervention: Standard mechanical compression (SC) in TRA subgroup
Number of subjects: 200
Study 31655876 — intervention group
Group type: EXPERIMENTAL
Intervention: QuikClot Radial hemostatic pad (QC) in TUA subgroup
Number of subjects: 200
Study 31655876 — intervention group
Group type: COMPARATOR
Intervention: Standard mechanical compression (SC) in TUA subgroup
Number of subjects: 200
Study 30458677 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐concept threat
Number of subjects: 0
Study 30458677 — intervention group
Group type: EXPERIMENTAL
Intervention: Own‐reputation threat
Number of subjects: 0
Study 30458677 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 29794581 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar total disc replacement (TDR)
Number of subjects: 126
Study 29794581 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 126
Study 29794581 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TDR and nonoperative treatment
Number of subjects: 126
Study 27078151 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO+PROT (0.8 g carbohydrate + 0.4 g protein·kg(‐1)·h(‐1))
Number of subjects: 8
Study 27078151 — intervention group
Group type: COMPARATOR
Intervention: CHO (1.2 g carbohydrate·kg(‐1)·h(‐1))
Number of subjects: 8
Study 27078151 — intervention group
Group type: COMPARATOR
Intervention: PLA (placebo without energy)
Number of subjects: 8
Study 24684807 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular microdialysis catheter
Number of subjects: 80
Study 24684807 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-lumen central venous catheter with integrated microdialysis function
Number of subjects: 80
Study 22445212 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication (fluoxetine or venlafaxine)
Number of subjects: 89
Study 22445212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 20073385 — intervention group
Group type: EXPERIMENTAL
Intervention: Worksite wellness program
Number of subjects: 82
Study 20073385 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 82
Study 17494789 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 31
Study 17494789 — intervention group
Group type: COMPARATOR
Intervention: APAP
Number of subjects: 31
Study 17494789 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CPAP and APAP
Number of subjects: 31
Study 15638752 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics and prebiotics
Number of subjects: 0
Study 15638752 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics and prebiotics in infant formula
Number of subjects: 0
Study 15638752 — intervention group
Group type: COMPARATOR
Intervention: Probiotic- and prebiotic-containing infant formulas
Number of subjects: 0
Study 12145773 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet + exercise group
Number of subjects: 29
Study 12145773 — intervention group
Group type: COMPARATOR
Intervention: Diet group
Number of subjects: 29
Study 10409957 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosidal K short-stretch compression bandage
Number of subjects: 52
Study 10409957 — intervention group
Group type: COMPARATOR
Intervention: SurePress long-stretch compression bandage
Number of subjects: 52
Study 7717556 — intervention group
Group type: EXPERIMENTAL
Intervention: Bullard laryngoscope
Number of subjects: 35
Study 7717556 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 35
Study 7717556 — intervention group
Group type: COMPARATOR
Intervention: Miller laryngoscope
Number of subjects: 35
Study 1828415 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg etodolac twice daily (n = 112)
Number of subjects: 220
Study 1828415 — intervention group
Group type: COMPARATOR
Intervention: 20 mg piroxicam once daily (n = 108)
Number of subjects: 220
Study 31601842 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg of pomegranate extract (PomX)
Number of subjects: 74
Study 31601842 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 oz of pomegranate juice (PomJ)
Number of subjects: 74
Study 31601842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 31601842 — intervention group
Group type: EXPERIMENTAL
Intervention: PomX and PomJ
Number of subjects: 74
Study 28765288 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up noncontrast computed tomography ischemic lesion volume (ILV) in brain areas of high mRS relevance
Number of subjects: 254
Study 28765288 — intervention group
Group type: EXPERIMENTAL
Intervention: Total ischemic lesion volume (ILV)
Number of subjects: 254
Study 26059264 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-concordant prescribing of ACE-inhibitors/statins in early clinics
Number of subjects: 6500
Study 26059264 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-concordant prescribing of statins in early clinics
Number of subjects: 6500
Study 26059264 — intervention group
Group type: COMPARATOR
Intervention: Control group (late clinics)
Number of subjects: 6500
Study 23348685 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal diet supplemented with 25% corn dried distillers grains (DDG)
Number of subjects: 21
Study 23348685 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal diet supplemented with 25% DDG with corn starch (DDG+S)
Number of subjects: 21
Study 23348685 — intervention group
Group type: COMPARATOR
Intervention: Corn grain-based basal diet (CON)
Number of subjects: 21
Study 21605389 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention based on Clinical Practice Guideline recommendations over a six-month period.
Number of subjects: 2937
Study 21605389 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract).
Number of subjects: 2937
Study 19139736 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-BM injection (IBMI) of one UCB unit
Number of subjects: 10
Study 19139736 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (i.v.) injection of one UCB unit
Number of subjects: 10
Study 19139736 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall outcomes
Number of subjects: 10
Study 17720409 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercostal muscle flap
Number of subjects: 70
Study 17720409 — intervention group
Group type: COMPARATOR
Intervention: Conventional resection
Number of subjects: 70
Study 15060361 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal/transnasal perforating lateral osteotomy (2‐mm straight chisel)
Number of subjects: 75
Study 15060361 — intervention group
Group type: EXPERIMENTAL
Intervention: External/percutaneous perforating lateral osteotomy (2‐mm straight chisel)
Number of subjects: 75
Study 15060361 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal transnasal perforating lateral osteotomy (2‐mm straight chisel)
Number of subjects: 75
Study 15060361 — intervention group
Group type: COMPARATOR
Intervention: Continuous osteotomy (4‐mm curved, guarded osteotome)
Number of subjects: 75
Study 11509937 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/kg intravenous immunoglobulin
Number of subjects: 618
Study 11509937 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg/kg intravenous immunoglobulin
Number of subjects: 618
Study 11509937 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg/kg intravenous immunoglobulin
Number of subjects: 618
Study 11509937 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of intravenous immunoglobulin
Number of subjects: 618
Study 11509937 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg/kg and 500 mg/kg intravenous immunoglobulin
Number of subjects: 618
Study 9604558 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% CO2-enriched air (unconditioned stimulus)
Number of subjects: 96
Study 9604558 — intervention group
Group type: EXPERIMENTAL
Intervention: 13% CO2-enriched air (unconditioned stimulus)
Number of subjects: 96
Study 7804585 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ibuprofen cream
Number of subjects: 100
Study 7804585 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 100
Study 3243930 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermally administered scopolamine (TTS-scopolamine) with acute alcohol intake (BAC 80 mg/dL)
Number of subjects: 12
Study 3243930 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermally administered scopolamine (TTS-scopolamine) with acute alcohol intake (BAC 130 mg/dL)
Number of subjects: 12
Study 3243930 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermally administered scopolamine (TTS-scopolamine)
Number of subjects: 12
Study 31172325 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive VR
Number of subjects: 31
Study 31172325 — intervention group
Group type: COMPARATOR
Intervention: Conventional VR
Number of subjects: 31
Study 29661991 — intervention group
Group type: EXPERIMENTAL
Intervention: Information on FDA roles in regulating tobacco
Number of subjects: 1766
Study 29661991 — intervention group
Group type: EXPERIMENTAL
Intervention: Information about the scientific basis of regulations
Number of subjects: 1766
Study 29661991 — intervention group
Group type: EXPERIMENTAL
Intervention: Information on FDA's commitment to protecting the public
Number of subjects: 1766
Study 29661991 — intervention group
Group type: COMPARATOR
Intervention: No information on FDA roles in regulating tobacco
Number of subjects: 1766
Study 29661991 — intervention group
Group type: COMPARATOR
Intervention: No information about the scientific basis of regulations
Number of subjects: 1766
Study 29661991 — intervention group
Group type: COMPARATOR
Intervention: No information on FDA's commitment to protecting the public
Number of subjects: 1766
Study 28466494 — intervention group
Group type: EXPERIMENTAL
Intervention: Demineralized freeze-dried cortical bone allograft
Number of subjects: 20
Study 28466494 — intervention group
Group type: COMPARATOR
Intervention: Deproteinized cancellous bovine bone xenograft
Number of subjects: 20
Study 25107900 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg IVT-AFL every 4 weeks (0.5q4)
Number of subjects: 94
Study 25107900 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg IVT-AFL every 4 weeks (2q4)
Number of subjects: 94
Study 25107900 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg IVT-AFL every 8 weeks (2q8)
Number of subjects: 94
Study 25107900 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg ranibizumab every 4 weeks (Rq4)
Number of subjects: 94
Study 24005242 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral prevention (CBP) program consisting of 8 weekly 90-minute group sessions followed by 6 monthly continuation sessions.
Number of subjects: 316
Study 24005242 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 316
Study 21439275 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid and vitamin B administration for 3 months in nondiabetic group
Number of subjects: 61
Study 21439275 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid and vitamin B administration for 3 months in diabetic group
Number of subjects: 61
Study 18513835 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bolus (OB) feeding
Number of subjects: 12
Study 18513835 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric tube bolus (TB) feeding
Number of subjects: 12
Study 18513835 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric tube drip (TD) feeding
Number of subjects: 12
Study 17186725 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling-blood and detoxicating combined with clearing-heat and resolving dampness (PA)
Number of subjects: 43
Study 17186725 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthening-Pi and warming-yang (PB)
Number of subjects: 43
Study 14662587 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk prethreshold ROP eyes (risk, 0.15-1.0)
Number of subjects: 613
Study 14662587 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk prethreshold ROP eyes (risk, <0.15)
Number of subjects: 613
Study 10735611 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin (2mg/iv injection)
Number of subjects: 20
Study 8866072 — intervention group
Group type: EXPERIMENTAL
Intervention: WTL + Prompt (leaflet provided and prompted to read)
Number of subjects: 66
Study 8866072 — intervention group
Group type: EXPERIMENTAL
Intervention: WTL only (leaflet provided but not prompted)
Number of subjects: 66
Study 8866072 — intervention group
Group type: COMPARATOR
Intervention: Control 1 (dental health education leaflet with no prompting)
Number of subjects: 66
Study 8866072 — intervention group
Group type: COMPARATOR
Intervention: Control 2 (no additional written material, verbal information provided)
Number of subjects: 66
Study 1477649 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGM‐CSF administered subcutaneously (s.c.)
Number of subjects: 24
Study 1477649 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGM‐CSF
Number of subjects: 24
Study 1477649 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGM‐CSF (5.5 and 11 micrograms/kg)
Number of subjects: 24
Study 1477649 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGM‐CSF (5.5 + 11 micrograms/kg)
Number of subjects: 24
Study 6367451 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy
Number of subjects: 0
Study 6367451 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition counseling based on a fat-modified eating pattern
Number of subjects: 0
Study 30686751 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation (100,000 UI once per week)
Number of subjects: 0
Study 30686751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30686751 — intervention group
Group type: EXPERIMENTAL
Intervention: Uremic serum
Number of subjects: 0
Study 30686751 — intervention group
Group type: EXPERIMENTAL
Intervention: 25(OH)D3 and 1,25(OH)2D3 incubation
Number of subjects: 0
Study 29465250 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole intravenous bolus every 12 hours for 72 hours with second look endoscopy
Number of subjects: 127
Study 29465250 — intervention group
Group type: COMPARATOR
Intervention: Continuous high dose esomeprazole infusion for 72 hours
Number of subjects: 127
Study 27974612 — intervention group
Group type: EXPERIMENTAL
Intervention: Active HD-tDCS on left DLPFC
Number of subjects: 120
Study 27974612 — intervention group
Group type: EXPERIMENTAL
Intervention: Active HD-tDCS on right DLPFC
Number of subjects: 120
Study 27974612 — intervention group
Group type: COMPARATOR
Intervention: Active HD-tDCS on left M1
Number of subjects: 120
Study 27974612 — intervention group
Group type: COMPARATOR
Intervention: Active HD-tDCS on right M1
Number of subjects: 120
Study 27974612 — intervention group
Group type: COMPARATOR
Intervention: Sham HD-tDCS on left DLPFC
Number of subjects: 120
Study 27974612 — intervention group
Group type: COMPARATOR
Intervention: Sham HD-tDCS on right DLPFC
Number of subjects: 120
Study 25085607 — intervention group
Group type: EXPERIMENTAL
Intervention: High-level endurance training combined with cognitive-behavioural therapy (CBT)
Number of subjects: 0
Study 25085607 — intervention group
Group type: COMPARATOR
Intervention: Low-level exercise combined with cognitive-behavioural therapy (CBT)
Number of subjects: 0
Study 21997554 — intervention group
Group type: EXPERIMENTAL
Intervention: High resolution manometry (HRM) Clouse plots
Number of subjects: 36
Study 21997554 — intervention group
Group type: COMPARATOR
Intervention: Conventional line tracings
Number of subjects: 36
Study 20417038 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Imagery (GI)
Number of subjects: 39
Study 20417038 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 39
Study 20417038 — intervention group
Group type: COMPARATOR
Intervention: Passive relaxation control condition
Number of subjects: 39
Study 20417038 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Imagery (GI) and Progressive Muscle Relaxation (PMR)
Number of subjects: 39
Study 17345071 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa 25 mg
Number of subjects: 0
Study 17345071 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa 50 mg
Number of subjects: 0
Study 17345071 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa 250 mg
Number of subjects: 0
Study 17345071 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa 100 mg (1 x 100 mg)
Number of subjects: 0
Study 17345071 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa 100 mg (3 x 100 mg over 3 hours)
Number of subjects: 0
Study 17345071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14699490 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir 10 mg daily + Lamivudine
Number of subjects: 135
Study 14699490 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine alone
Number of subjects: 135
Study 14699490 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir + Lamivudine (group B)
Number of subjects: 135